NUTX (Nutex Health Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NUTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | Scott J Saunders | Director | Sell | — | — |
| 2026-08-03 | Cheryl Yvonne Grenas | Director | M | — | — |
| 2026-08-03 | Scott J Saunders | Director | M | — | — |
| 2026-08-03 | Frank E Jaumot | Director | M | — | — |
| 2026-08-03 | Michael Lee Reed | Director | M | — | — |
| 2026-06-04 | Kelvin Spears | Director | J | — | — |
| 2026-05-29 | Thomas T. Vo | Chief Executive Officer | J | — | — |
| 2026-04-24 | Cheryl Yvonne Grenas | Director | A | — | — |
| 2026-04-24 | Michael Lee Reed | Director | A | — | — |
| 2026-04-24 | Frank E Jaumot | Director | A | — | — |
| 2026-04-24 | Scott J Saunders | Director | A | — | — |
| 2026-04-10 | Thomas T. Vo | Chief Executive Officer | J | — | — |
| 2026-03-24 | Wesley Shane Bamburg | Chief Operating Officer | M | — | — |
| 2026-03-23 | Frank E Jaumot | Director | Buy | — | — |
| 2026-03-23 | Warren Hosseinion | President | Buy | — | — |
| 2026-03-18 | Kelvin Spears | Director | Buy | — | — |
| 2026-03-16 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | Buy | — | — |
| 2026-03-11 | Jon Christian Bates | Chief Financial Officer | M | — | — |
| 2026-03-11 | Warren Hosseinion | President | MIXED | — | — |
| 2026-03-11 | Thomas T. Vo | Chief Executive Officer | MIXED | — | — |
| 2026-03-11 | Kelvin Spears | Director | MIXED | — | — |
| 2026-03-11 | Michael L. Chang | Chief Medical Officer | MIXED | — | — |
| 2026-03-11 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | MIXED | — | — |
| 2026-03-11 | Elisa V Luqman | Chief Legal Officer - SEC | MIXED | — | — |
| 2026-02-09 | Frank E Jaumot | Director | A | — | — |
| 2026-02-09 | Michael Lee Reed | Director | A | — | — |
| 2026-02-09 | Cheryl Yvonne Grenas | Director | A | — | — |
| 2026-02-09 | Scott J Saunders | Director | A | — | — |
| 2025-11-28 | Jon Christian Bates | Chief Financial Officer | Buy | — | — |
| 2025-04-14 | Warren Hosseinion | President | MIXED | — | — |
| 2025-04-14 | Joshua DeTillio | Chief Operating Officer | MIXED | — | — |
| 2025-04-14 | Jon Christian Bates | Chief Financial Officer | MIXED | — | — |
| 2025-04-14 | Kelvin Spears | Director | MIXED | — | — |
| 2025-04-14 | Elisa V Luqman | Chief Legal Officer - SEC | MIXED | — | — |
| 2025-04-14 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | MIXED | — | — |
| 2025-04-14 | Thomas T. Vo | Chief Executive Officer | MIXED | — | — |
| 2025-04-14 | Michael L. Chang | Chief Medical Officer | MIXED | — | — |
| 2025-01-10 | Thomas T. Vo | Chief Executive Officer | G | — | — |
| 2024-08-26 | Jon Christian Bates | Chief Financial Officer | Buy | — | — |
| 2024-08-21 | Joshua DeTillio | Chief Operating Officer | Buy | — | — |
| 2024-07-15 | Thomas T. Vo | Chief Executive Officer | A | — | — |
| 2024-06-28 | Elisa V Luqman | Chief Legal Officer-SEC | A | — | — |
| 2024-06-28 | Thomas T. Vo | Chief Executive Officer | A | — | — |
| 2024-06-28 | Warren Hosseinion | President | A | — | — |
| 2024-06-28 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | A | — | — |
| 2024-06-28 | Warren Hosseinion | President | A | — | — |
| 2024-06-28 | Joshua DeTillio | Chief Operating Officer | A | — | — |
| 2024-06-28 | Michael L. Chang | Chief Medical Officer | A | — | — |
| 2024-06-28 | Jon Christian Bates | Chief Financial Officer | A | — | — |
| 2024-06-13 | Joshua DeTillio | Chief Operating Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 2,281,060 | — |
| — | 10%+ Owner | 1,782,152 | — |
| — | Director | 280,895 | — |
| — | 10%+ Owner | 279,766 | — |
| — | Chief Medical Officer | 82,356 | — |
| — | Director | 34,656 | — |
| — | Chief Financial Officer | 8,305 | — |
| — | President | 7,765 | — |
| — | Chief Operating Officer | 6,933 | — |
| — | Chief Legal Officer - SEC | 3,706 | — |
| — | Retired CFO | 2,977 | — |
| — | Chief Legal Officer-Healthcare | 2,758 | — |
| — | Chief Medical Information Off | 1,691 | — |
| — | Director | 1,308 | — |
| — | Director | 753 | — |
| — | Director | 737 | — |
| — | Director | 670 | — |
| — | Director | 545 | — |
| — | Director | 400 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NUTX quote page; the site-wide leaderboard is on the insider transactions hub.